View Older Stories View More Recent Stories

Mar 29, 2022 05:55AM Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO), Sees Upward Earnings Revisions and Multiple Expansion

Mar 29, 2022 05:54AM Cantor Fitzgerald Reiterates Overweight Rating on Arcutis Biotherapeutics (ARQT)

Mar 29, 2022 05:52AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Mar 29, 2022 05:51AM Cowen Reiterates Outperform Rating, $12 PT on Ginkgo Bioworks Holdings Inc (DNA) Following Earnings

Mar 28, 2022 11:56AM William Blair Reiterates Outperform Rating on Eagle Pharmaceuticals (EGRX), Sees Multiple Possibilities for Further Upside

Mar 28, 2022 11:23AM Dawson James Reiterates Buy Rating on Fortress Biotech (FBIO)

Mar 28, 2022 11:13AM Cowen Reiterates Outperform Rating on uniQure BV (QURE), Continues to View Shares as Undervalued Based on CSL Deal

Mar 28, 2022 11:10AM UPDATE: HUTCHMED (China) (HCM) and Viatris (VTRS) Top Cantor Fitzgerald's List of Biggest Short Interest Increases, Heron (HRTX) and Omeros (OMER) Continue to Have Higher Short Floats

Mar 28, 2022 10:39AM Cowen Reiterates Outperform Rating on Krystal Biotech (KRYS), "Remain Encouraged by New Durability Analyses"

Mar 28, 2022 10:28AM Mizuho Securities Reiterates Arcutis Biotherapeutics (ARQT) at Buy, $58 PT, Company Has a Good Risk/Reward

Mar 28, 2022 07:50AM Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy Following Sunosi Deal, Sees it as a Positive

Mar 28, 2022 06:57AM Vir Biotechnology (VIR) PT Slashed to $45 at Needham & Company on sotrovimab Issues

Mar 25, 2022 03:19PM PhaseBio Pharmaceuticals (PHAS) PT Slashed to $10 by Needham, Buy Reiterated, Sees bentracimab's Potential Undervalued Despite Capital Overhang

Mar 25, 2022 10:04AM "Near-Term Zandelisib Launch off the Table" After "Bewildering" FDA Feedback - MEI Pharma (MEIP) Stock Crashes as Analysts Downgrades Roll In

Mar 25, 2022 06:15AM MEI Pharma (MEIP) PT Lowered to $3 at Truist Securities on zandelisib Delay, but Maintains Conviction in Drug, Sees Peak Sales of $94M

Mar 25, 2022 06:12AM Stifel Reiterates Buy Rating. $12 PT on Equillium (EQ), Believes Phase 3 Study is "An Important Stepping Stone in Unlocking Pipeline Potential"

Mar 24, 2022 05:15PM Stifel Reiterates Buy Rating on Fulcrum Therapeutics (FULC) With $43 PT, Sees Losmapimod Trial as a "Meaningful Binary Catalyst for the Stock"

Mar 24, 2022 03:54PM Cowen Reiterates Outperform Rating on Evelo Biosciences Inc (EVLO)

Mar 24, 2022 12:08PM Cantor Fitzgerald Reiterates ContraFect (CFRX) at Overweight with $15 PT, Expects Upwards Earnings Revisions

Mar 24, 2022 10:03AM Collplant Holdings Inc. (CLGN) PT Lowered to $17 at Dawson James on Lower Near-Term Revenue Guidance, but Analyst Sees "Lots of Potential in 3D Bioprinting"

Mar 24, 2022 09:35AM Stifel Reiterates Buy Rating on Freeline (FRLN), Sees FLT190 Updates as Positive, but Needs More Clearance into True Therapeutic Benefit

Mar 24, 2022 06:58AM Oppenheimer Reiterates Outperform Rating on Mustang Bio (MBIO), Continues to See CD20 CAR-T Program as Main Value Driver

Mar 24, 2022 06:24AM Homology Medicines (FIXX) PT Lowered to $4 at Stifel on Lack of Visibility into Clinical Hold Resolution, Awaits More Specific Updates

Mar 24, 2022 06:22AM Truist Securities Reiterates Aptinyx (APTX) at Buy with $12 PT, Sees Risk/Reward Skewed to Upside at Current Valuation

Mar 24, 2022 06:20AM Cowen Reiterates Zymergen (ZY) at Market Perform, Sees Potential Recovery in Stock on SynBio Opportunity

Mar 24, 2022 06:13AM Needham & Company Reiterates Buy Rating, $50 PT on Celcuity Inc (CELC)

Mar 24, 2022 06:11AM H.C. Wainwright Reiterates Buy Rating, $7 PT on Mustang Bio (MBIO), Sees MB-102 in AML and MDS as Key Opportunity

Mar 23, 2022 05:02PM Cantor Fitzgerald Reiterates Aspira Women’s Health (AWH) at Overweight with $4 PT, Sees Shares as "Materially Undervalued"

Mar 23, 2022 04:14PM William Blair Reiterates Outperform Rating on 9 Meter Biopharma (NMTR), Shares Have Assymetric Risk/Reward

Mar 23, 2022 11:19AM Cowen Reiterates Outperform Rating on Moderna (MRNA), Sees Latest Kids Data as Providing a Strategic Benefit

Mar 23, 2022 10:48AM H.C. Wainwright Reiterates Buy Rating on XOMA (XOMA)

Mar 23, 2022 10:43AM Truist Securities Reiterates Buy Rating on Roivant Sciences (ROIV)

Mar 23, 2022 10:27AM Cantor Fitzgerald Reiterates Aytu Biosciences (AYTU) at Overweight, $11 PT, Sees it as Positive Development Potentially Extending ADHD Franchise Revenue Runway

Mar 23, 2022 10:12AM Truist Securities Reiterates Immunovant (IMVT) at Buy, $12 PT, Sees batoclimab Peak Sales of $430M Across Two Indications

Mar 23, 2022 09:55AM Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD), Sees Launch in Three New Areas as Favorable and as an Important Commercialization Milestone

Mar 23, 2022 09:44AM Cantor Fitzgerald Reiterates Pfizer (PFE) at Overweight Rating with $75 PT on Phase 3 etrasimod Data

Mar 23, 2022 08:08AM Cowen Reiterates Outperform on Codex DNA (DNAY), Remains Positive on Long-Term Outlook, Highlights Robust Growth of BioXp 9600 Despite Delayed Launch

Mar 23, 2022 07:54AM BMO Capital Reiterates Pfizer (PFE) at Ourperform, $76 PT, Sees etrasimod Better Positioned vs BMY's Zeposia

Mar 23, 2022 07:51AM Exagen (XGN) PT Lowered to $19 at Cantor Fitzgerald on Weaker Guidance, but Analyst Maintained Overweight Rating and Positive Outlook, "Would Encourage Investors to Acquire Shares" at Current Valuatio

Mar 23, 2022 07:37AM Dawson James Reiterates Better Choice (BTTR) at Buy, $10 PT on Halo Elevate Launch, Sees 40% Growth Across Segments and Rapidly Expanding Margins

Mar 23, 2022 06:18AM Stifel Reiterates Buy Rating on Atara Biotherapeutics (ATRA) with $20 PT, Sees Huge Market Potential for ATA188 on Positive Trial Outcome but Warns of Low Probability of Success

Mar 23, 2022 06:14AM Cowen Reiterates Krystal Biotech (KRYS) at Outperform, $111 PT, Encouraged by Impressive Skin Changes of KB301 Which "FDA Places Significant Weight On"

Mar 23, 2022 06:10AM H.C. Wainwright Reiterates Aptose Biosciences (APTO) at Buy with $12 PT, Sees HM43239 as Key Potential Value Driver

Mar 23, 2022 06:05AM Mizuho Securities Reiterates Arcutis Biotherapeutics (ARQT) at Buy with $58 PT, Cites De-Risked Phase 3 Trials and High Likelihood of FDA Approval of roflumilast Cream

Mar 22, 2022 04:18PM Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy, Believes ALNY Has More Overlooked Catalysts than Most Peers

Mar 22, 2022 12:48PM Cowen Reiterates Outperform Rating on Terns Pharmaceuticals (TERN), Believes VAP-1 is Not Well Understood and Could be Underappreciated

Mar 22, 2022 12:13PM Krystal Biotech (KRYS) PT Lowered to $107 at H. C. Wainwright, Buy Rating Maintained Ahead of Vyjuvek Launch

Mar 22, 2022 12:04PM Mizuho Securities Reiterates TCR2 Therapeutics (TCRR) at Buy, $20 PT, Sees Meaningful Upside on Phase 2 Data, Views 2023 Readout as Another Major Opportunity

Mar 22, 2022 11:23AM Stifel Reiterates Hold Rating on Vertex (VRTX), Sees VX-147 a "Big Drug" in Bull-case Scenario

Mar 22, 2022 11:08AM Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, Believes New Vaccine Candidates Present Potential Upside to Long-Term Outlook

View More Recent Stories View Older Stories